Sy Mukherjee, Fortune

Sy Mukherjee


New York, NY, United States

Contact Sy

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Learn more here

  • Fortune

Recent articles by Sy:

These Were the 10 Biggest Pharmaceutical Deals of 2016

A new EP Vantage report lists the 10 biggest biotech and pharmaceutical industry deals of 2016. Overall deal value declined. → Read More

U.S. Life Expectancy Is Projected to Fall Even Further Behind Other Countries

A new study suggests that U.S. life expectancy will still lag behind nations like South Korea and other developed nations in 2030. → Read More

Same Sex Marriage Legalization May Have Cut Teen Suicide Attempts

State legalization of same sex marriage may have helped drive down teen suicide attempts, according to a new study. → Read More

Gilead Just Paid $125 Million to Nab a Big Market Advantage

The biotech giant can now speed up the drug review process. → Read More

Theranos Is Running Dangerously Low on Cash

Blood testing startup Theranos had just $200 million in cash at the end of 2016, according to the Wall Street Journal. → Read More

This Insurance Giant’s CEO Thinks That Obamacare Is in a ‘Death Spiral’

Aetna CEO Mark Bertolini thinks that Obamacare's marketplaces are in a death spiral and won't be getting better anytime soon. → Read More

Why Drug Companies Don’t Want President Trump to Deregulate the FDA

President Donald Trump's promise to slash FDA regulations isn't sitting well with executives from Merck, Alnylam, and other drug makers. → Read More

Drug Company Hits Pause on Launching an $89,000 Muscular Dystrophy Drug After Backlash

Marathon Pharma hit the "pause" button on the launch of a newly approved drug to treat Duchenne muscular dystrophy after a pricing backlash. → Read More

President Trump’s Election Didn’t Help Obamacare Signups

12.2 million Americans signed up for Obamacare plans this year, according to the Associated Press. Did Trump's election hurt the numbers? → Read More

This Pharma Company Is Selling a Decades-old Drug to Treat Muscular Dystrophy for $89,000

Marathon Pharmaceuticals is set to sell a cheap, decades-old Duchenne muscular dystrophy drug for $89,000 in the U.S. → Read More

Check Out This Map of the Most Distinctive Injuries in Each State

Digital health firm Amino has produced maps of the most common injury types in the U.S. - and the most distinctive ones in each state. → Read More

We Just Learned a Lot More About How Badly Theranos Labs Screwed Up

A federal inspection report details numerous procedural and technical failures at the embattled blood testing startup Theranos. → Read More

The 10 Most Promising Health Care Jobs of 2017

LinkedIn is out with a list of the 10 most promising health care jobs of 2017 — and, no, you don't have to be a doctor to apply to plenty of them → Read More

The Next Big Brain Cancer Drug Could Come from Marijuana

GW Pharmaceuticals has a marijuana-derived drug that may effectively treat one of the most devastating forms of brain cancer. → Read More

More Than 150 Biotech Leaders Sent President Trump a Letter Slamming His Travel Ban

More than 150 biotech CEOs slammed President Donald Trump's travel ban in an open letter published Tuesday. → Read More

IBM’s Supercomputer Is Bringing AI-Fueled Cancer Care to Everyday Americans

It's Watson for Oncology's first partnership with a community hospital. → Read More

Big Pharma CEOs Met With Trump But They Won’t Give In to His Demands

President Donald Trump met with major pharma CEOs from Merck, Novartis, and others. But they won't be able to grant his wish list. → Read More

NFL Concussions Still Significant In 2016 Despite Modest Decline

Head injury rates remained alarmingly high in 2016. → Read More

This Pharma Giant Just Pulled Back the Curtain On Its Drug Price Hikes

Merck just released a whole lot more information about its practices. → Read More

Stanford’s Artificial Intelligence Is Nearly as Good as Your Dermatologist

Deep learning strikes again. → Read More